Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (89)	8/21/2001 9:36:00 AM
From: tuck	Read Replies (1) \| Respond to of 254

>>THE WOODLANDS, Texas, Aug. 21 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) announced today the senior leadership for its High-Throughput Screening and Medicinal Chemistry programs. Combined, these groups are expected to enable Lexicon to maximize the value of its biologically validated targets by providing optimized leads for drug development. ``Lexicon has assembled the expertise to rapidly implement an integrated gene-to-lead drug discovery platform,'' said Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Lexicon. ``By combining our in vivo mammalian validated targets with Lexicon Pharmaceuticals' highly efficient and proven chemical approaches to discover small molecule drugs, we are well positioned to capture significantly higher value from the drug targets we have discovered.'' To facilitate these initiatives, S. David Kimball, Ph.D., has joined Lexicon as Senior Director of Medicinal Chemistry and will be based at Lexicon Pharmaceuticals in Princeton, NJ. In his new position, Dr. Kimball will complement the Company's industrialized medicinal chemistry program by optimizing hits against Lexicon's lead target candidates. Before joining Lexicon, Dr. Kimball spent 19 years at the Bristol-Myers Squibb Pharmaceutical Research Institute, most recently as Research Fellow in the Division of Medicinal Chemistry, Princeton, NJ. During his tenure at the Institute, Dr. Kimball led several significant drug discovery and development research efforts. These involved molecular targets in oncology, serine protease inhibitors of blood coagulation and ion channel modulators for the treatment of hypertension and angina. Dr. Kimball has also been an Associate Member of the Graduate Faculty at Rutgers University School of Pharmacy since 1989. Dr. Kimball earned a Ph.D. in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook. C. Alexander Turner, Jr., Ph.D., has been named Senior Director, Pharmaceutical Discovery, and continues to be based at Lexicon's Genome Pharmaceutical Discovery Center in The Woodlands, Texas. In his new position, Dr. Turner is responsible for assay development and high-throughput screening of small molecule compounds against Lexicon's proprietary in vivo validated drug targets. Dr. Turner joined Lexicon in 1996 as a Scientist and most recently has served as Director of Molecular Biology with responsibility for gene expression analysis, full-length gene cloning, protein expression, and functional genomics database curation. Prior to joining Lexicon, Dr. Turner was a Research Fellow in Pediatrics at Children's Hospital in Boston from 1993 to 1996. Dr. Turner holds a Ph.D. in Microbiology and Immunology from Stanford University and a bachelor's degree from Harvard College. Peter H. Cheung, Ph.D., has joined Lexicon as Senior Scientist in Pharmaceutical Discovery and is based at Lexicon's Genome Pharmaceutical Discovery Center in The Woodlands, Texas. Dr. Cheung's extensive background in chemistry and pharmacology, as well as his six years' experience leading high-throughput screening efforts as Senior Scientist, Growth Factor Team, at R.W. Johnson Pharmaceutical Research Institute, will facilitate the rapid implementation of Lexicon's high-throughput screening efforts. Dr. Cheung holds a Ph.D. in Pharmacology from the University of Nebraska Medical Center, an M.S. in Chemistry from Creighton University and B.S. degrees in chemistry and computer science from Creighton and the University of Nebraska, respectively.<< snip Cheers, Tuck